Get the Stockscreener App
1.335
2.55%
-0.035
After Hours:
1.25
-0.085
-6.37%
Galmed Pharmaceuticals Ltd stock is traded at $1.335, with a volume of 51,968.
It is down -2.55% in the last 24 hours and down -14.97% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.37
Open:
$1.34
24h Volume:
51,968
Relative Volume:
0.41
Market Cap:
$7.31M
Revenue:
-
Net Income/Loss:
$-8.72M
P/E Ratio:
-0.2433
EPS:
-5.4871
Net Cash Flow:
$-5.47M
1W Performance:
-3.26%
1M Performance:
-14.97%
6M Performance:
+6.80%
1Y Performance:
-58.80%
1-Day Range:
$1.335
$1.355
1-Week Range:
$1.30
$1.5265
52-Week Range:
$1.15
$3.61
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.335 | 7.51M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth eraWeekly Trend Summary & Safe Capital Investment Plans - newser.com
What Fibonacci levels say about Galmed Pharmaceuticals Ltd. rebound2025 Dividend Review & Daily Chart Pattern Signal Reports - newser.com
Why Galmed Pharmaceuticals Ltd. stock attracts global investorsTrade Signal Summary & Safe Capital Allocation Plans - newser.com
Multi factor analysis applied to Galmed Pharmaceuticals Ltd.Quarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investingJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Key metrics from Galmed Pharmaceuticals Ltd.’s quarterly dataJuly 2025 Setups & Weekly High Return Forecasts - newser.com
Analyzing drawdowns of Galmed Pharmaceuticals Ltd. with statistical toolsJuly 2025 Trade Ideas & Entry Point Confirmation Signals - newser.com
How Galmed Pharmaceuticals Ltd. stock reacts to inflationary pressuresBuy Signal & Accurate Entry/Exit Alerts - newser.com
How to track smart money flows in Galmed Pharmaceuticals Ltd.Trade Risk Summary & Weekly High Return Stock Opportunities - newser.com
Why Galmed Pharmaceuticals Ltd. stock is trending among retail tradersQuarterly Earnings Summary & Weekly Return Optimization Alerts - newser.com
Can you recover from losses in Galmed Pharmaceuticals Ltd.Trade Risk Assessment & Low Volatility Stock Recommendations - newser.com
Galmed Pharmaceuticals Secures Shareholder Approval at Annual Meeting - TipRanks
Galmed (GLMD) AGM proposals approved; filing incorporated into registration statements - Stock Titan
Galmed Pharmaceuticals Reschedules Annual General Meeting Due to Lack of Quorum - TipRanks
Galmed 6-K: AGM delayed for quorum; new time Oct 29, 4:00 p.m. - Stock Titan
Should I hold or sell Galmed Pharmaceuticals Ltd. stock in 2025Trade Analysis Report & AI Based Buy/Sell Signal Reports - fcp.pa.gov.br
What to do if you’re stuck in Galmed Pharmaceuticals Ltd.Portfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):